Teva Sees FY23 Revenues Outlook Of $15.1B-$15.5B Compared To Prior Guidance Of $15B-$15.4B And Consensus Of $15.17B
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Industries Ltd. has updated its FY23 revenue outlook to $15.1B-$15.5B, up from the previous guidance of $15B-$15.4B. This is also higher than the consensus estimate of $15.17B.
November 08, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva's updated FY23 revenue outlook is higher than both its previous guidance and the consensus estimate, indicating potential growth.
Teva's updated revenue outlook for FY23 is higher than its previous guidance and the consensus estimate. This suggests that the company expects stronger performance and growth, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100